Study Description

Brief summary:

The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).

• Condition or Disease:Autoimmune Disorder
  Rheumatoid Arthritis
  Systemic Lupus Erythematosus
  Primary Sjögren's Syndrome
• Intervention/Treatment: Drug: branebrutinib
  Drug: abatacept
  Drug: branebrutinib placebo
• Phase: Phase 2

Detailed Description

N/A

Study Design

Arms and interventions

Outcome Measures

• Primary Outcome Measures: 1. Systemic lupus erythematosus (SLE): Modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI) activity score response [ Time Frame: at 24 weeks ]
  Proportion of participants with a ≥ 50% reduction of mCLASI from baseline
• Primary Outcome Measures: 2. pSS: Proportion of participants with changes in a composite score that includes ESSPRI (EULAR Sjögren's Syndrome Patient Reported Index), ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index), ocular staining, salivary flow and serological marker [ Time Frame: at 24 weeks ]
  
• Primary Outcome Measures: 3. Rheumatoid arthritis (RA): ACR50 response [ Time Frame: at 12 weeks ]
  Proportion of participants achieving ACR50 response (American College of Rheumatology 50 criteria)
• Secondary Outcome Measures: 1. SLE: SLEDAI-2K score response [ Time Frame: at 24 weeks ]
  Change from baseline in SLEDAI-2K score (Systemic Lupus Erythematosus Disease Activity Index 2000)
• Secondary Outcome Measures: 2. SLE: BILAG-based Composite Lupus Assessment response [ Time Frame: at 24 weeks ]
  Change from baseline in BILAG-based (British Isles Lupus Assessment Group) Composite Lupus Assessment response
• Secondary Outcome Measures: 3. RA: DAS28-CRP response [ Time Frame: at 12 weeks ]
  Change from baseline in DAS28-CRP (Disease Activity Score 28 - C reactive protein)
• Secondary Outcome Measures: 4. RA: DAS28-ESR response [ Time Frame: at 12 weeks ]
  Change from baseline in DAS28-ESR (Disease Activity Score 28 - Erythrocyte Sedimentation Rate)
• Secondary Outcome Measures: 5. RA: SDAI response [ Time Frame: at 12 weeks ]
  Change from baseline in SDAI (Simplified Disease Activity Index)
• Secondary Outcome Measures: 6. RA: CDAI response [ Time Frame: at 12 weeks ]
  Change from baseline in CDAI (Clinical Disease Activity Index)
• Secondary Outcome Measures: 7. RA: ACR20 response [ Time Frame: at 12 weeks ]
  Proportion of participants achieving ACR20 response (American College of Rheumatology 20 criteria)
• Secondary Outcome Measures: 8. RA: ACR70 response [ Time Frame: at 12 weeks ]
  Proportion of participants achieving ACR70 response (American College of Rheumatology 70 criteria)
• Secondary Outcome Measures: 9. Number of participants with adverse events (AEs) [ Time Frame: Up to 32 weeks ]
  
• Secondary Outcome Measures: 10. Number of participants with clinical laboratory abnormalities [ Time Frame: Up to 32 weeks ]
  
• Secondary Outcome Measures: 11. Number of participants with vital sign abnormalities [ Time Frame: Up to 32 weeks ]
  
• Secondary Outcome Measures: 12. Number of participants with electrocardiogram (ECG) abnormalities [ Time Frame: Up to 32 weeks ]
  

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.

-->

• Ages Eligible for Study: 18 to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

More Information

• Responsible Party: Bristol-Myers Squibb
• ClinicalTrials.gov Identifier: NCT04186871 History of Changes
• Other Study ID Numbers: IM014-029, 2019-002205-22
• First Posted: December 5, 2019 Key Record Dates
• Last Update Posted: July 22, 2022
• Last Verified: July 2022
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Rheumatic Diseases
  Connective Tissue Diseases
  Immune System Diseases
  Xerostomia
  Salivary Gland Diseases
  Mouth Diseases
  Stomatognathic Diseases
  Dry Eye Syndromes
  Lacrimal Apparatus Diseases
  Eye Diseases Arthritis
  Arthritis, Rheumatoid
  Sjogren's Syndrome
  Lupus Erythematosus, Systemic
  Autoimmune Diseases
  Syndrome
  Disease
  Pathologic Processes
  Joint Diseases
  Musculoskeletal Diseases